135 related articles for article (PubMed ID: 38527504)
21. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
[No Abstract] [Full Text] [Related]
22. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
23. [Clinical Significance of Minimal Residual Disease in Risk Stratification and Prognosis of Childhood B-lineage Acute Lymphoblastic Leukemia].
An FY; Zhang SH; Kong LJ; Liang Y; Xu JX; He HL; Chai YH; Zhao WL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):729-735. PubMed ID: 28641626
[TBL] [Abstract][Full Text] [Related]
24. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
[TBL] [Abstract][Full Text] [Related]
25. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
[TBL] [Abstract][Full Text] [Related]
26. [Clinical Characteristics and Prognosis of
Li M; Zheng YZ; Li J; LE SH; Zheng H; Chen ZS; Weng KZ; Zhuang SQ; Wu XG; Wen H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(4):973-979. PubMed ID: 37551464
[TBL] [Abstract][Full Text] [Related]
27. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
[TBL] [Abstract][Full Text] [Related]
29. The therapeutic efficacy of pediatric ALL patients with MLL gene rearrangement treated with CCLG-ALL2008 protocol.
Sun YN; Hu YX; Gao L; Xiao PF; Lu J; Wu SY; Wang M; Shao XJ; Zhou CY; Ling J; Li JQ; Pan J; Gao J; Hu SY
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):6020-6029. PubMed ID: 30280786
[TBL] [Abstract][Full Text] [Related]
30. The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia.
Xue YJ; Wang Y; Jia YP; Zuo YX; Wu J; Lu AD; Zhang LP
Int J Hematol; 2021 Apr; 113(4):547-555. PubMed ID: 33386596
[TBL] [Abstract][Full Text] [Related]
31. [Prognostic Significance of Joint Detection of miR-210 and Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia].
Mei YY; Li ZG; Zhang Y; Zhang WL; Zhang PW; Wang N; Huang DS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):66-71. PubMed ID: 28245377
[TBL] [Abstract][Full Text] [Related]
32. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
Wang Y; Zeng HM; Zhang LP
Ital J Pediatr; 2018 Aug; 44(1):94. PubMed ID: 30115129
[TBL] [Abstract][Full Text] [Related]
33. [The Best Time of Minimal Residual Disease Monitoring for Predicting Survival and Prognosis in Children with T-Cell Acute Lymphoblastic Leukemia].
Bao H; Li TY; Wu YT; Xiao ZT; Zhang L; Luo LY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1471-1477. PubMed ID: 34627426
[TBL] [Abstract][Full Text] [Related]
34. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
35. [The Factors Affecting Relapse in Pediatric B-cell Acute Lymphoblastic Leukemia Patients without Prognostic Fusion Genes Following Up for 10 years].
Jiang MY; Gao W; Gao J; Ling J; Pan J; Xiao PF; Lu J; He HL; Wang Y; Li J; Li JQ; Chai YH; Sun YN; Hu SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):12-17. PubMed ID: 35123597
[TBL] [Abstract][Full Text] [Related]
36. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study.
Zhu Y; Zhu Y; Miao L; Jia T; Mao J; Xue L; Wang Y
Technol Cancer Res Treat; 2023; 22():15330338231165866. PubMed ID: 36959735
[TBL] [Abstract][Full Text] [Related]
38. [Outcome of childhood T-cell acute lymphoblastic leukemia: a report of 99 cases].
Cai JY; Xue HL; Chen J; Shen SH; Pan C; Wang X; Zhou M; Tang YJ; Gao YJ; Wang JM; Tang JY
Zhonghua Er Ke Za Zhi; 2016 Jun; 54(6):456-60. PubMed ID: 27256235
[TBL] [Abstract][Full Text] [Related]
39. [Long-term results of multicenter study based on childhood acute lymphoblastic leukemia 2005 protocol].
Cai JY; Wang NL; Jiang H; Shen SH; Xue HL; Chen J; Pan C; Gao YJ; Sun LR; Yuan XJ; Gu LJ; Tang JY
Zhonghua Er Ke Za Zhi; 2018 Jul; 56(7):511-517. PubMed ID: 29996184
[No Abstract] [Full Text] [Related]
40. [Clinical significance of sequential monitoring minimal residual disease in childhood B-cell acute lymphoblastic leukemia].
Wang L; Jiang H; Li H; Shao JB; Lu ZH; Yang JW; Yang WQ
Zhonghua Xue Ye Xue Za Zhi; 2011 Jun; 32(6):400-3. PubMed ID: 21781499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
